Advertisement

State of the science: Evolving role of surgery for the treatment of ovarian cancer

Published:August 28, 2019DOI:https://doi.org/10.1016/j.ygyno.2019.08.016
      While surgery combined with systemic chemotherapy has remained the foundation of ovarian cancer treatment, the scope, timing, and overall philosophy surrounding surgical debulking has continued to evolve. There is abundant controversy regarding certain aspects of ovarian cancer management, including the role of neoadjuvant chemotherapy (NACT) and the timing of cytoreductive surgery. Over the past 3 decades, however, one factor has remained unchanged: volume of residual disease after debulking surgery is a strong prognostic factor in ovarian cancer, reinforcing the importance and relevance of surgical effort in the care of these patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Harter P.
        • Sehouli J.
        • Lorusso D.
        • et al.
        A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms.
        N. Engl. J. Med. 2019 Feb 28; 380: 822-832
        • Panici P.B.
        • Maggioni A.
        • Hacker N.
        • et al.
        Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
        J. Natl. Cancer Inst. 2005 Apr 20; 97: 560-566
        • van Driel W.J.
        • Koole S.N.
        • Sikorska K.
        • et al.
        Hyperthermic intraperitoneal chemotherapy in ovarian cancer.
        N. Engl. J. Med. 2018 Jan 18; 378: 230-240
        • Vergote I.
        • Trope C.G.
        • Amant F.
        • et al.
        Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
        N. Engl. J. Med. 2010 Sep 2; 363: 943-953
        • Kehoe S.
        • Hook J.
        • Nankivell M.
        • et al.
        Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open label, randomized, controlled, non-inferiority trial.
        Lancet. 2015 Jul 18; 386: 249-257
        • Onda T.
        • Satoh T.
        • Saito T.
        • et al.
        Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
        Eur. J. Cancer. 2016 Sep; 64: 22-31
        • Onda T.
        • Satoh T.
        • Saito T.
        • et al.
        Comparison of Survival Between Upfront Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal and Peritoneal Cancers in Phase III Randomized Trial: JCOG0602.
        ASCO Abstract, 2018
        • Fagotti A.
        • Ferrandina G.
        • Vizzielli G.
        • et al.
        Phase III randomized clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome.
        Eur. J. Cancer. 2016 May; 59: 22-33
        • Fagotti
        • et al.
        Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial).
        in: ASCO Abstract. 2018
        • Armstrong D.K.
        • Bundy B.
        • Wenzel L.
        • et al.
        Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
        N. Engl. J. Med. 2006 Jan 5; 354: 34-43
        • Mueller J.J.
        • Zhou Q.C.
        • Iasonos A.
        • et al.
        Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
        Gynecol. Oncol. 2016 Mar; 140: 436-442
        • Fleming N.D.
        • Nick A.M.
        • Coleman R.L.
        • et al.
        Laparoscopic surgical algorithm to triage the timing of tumorreductive surgery in advanced ovarian cancer.
        Obstet. Gynecol. 2018 Sept; 132: 545-554
        • Tseng J.H.
        • Cowan R.A.
        • Zhou Q.
        • et al.
        Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival?.
        Gynecol. Oncol. 2018 Oct; 151: 24-31
        • Berek J.S.
        • Hacker N.F.
        • Lagasse L.D.
        Survival of patients following secondary cytoreductive surgery in ovarian cancer.
        Obstet. Gynecol. 1983 Feb; 61: 189-193
        • Segna R.
        • Dottino P.R.
        • Mandeli J.P.
        • et al.
        Secondary cytoreductive surgery for ovarian cancer following cisplatin therapy.
        J. Clin. Oncol. 1993 Mar; 11: 434-439
      1. Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011, Spt 27;105(7):890–6.

        • Harter P.
        • du Bois A.
        • Hahmann M.
        • et al.
        Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
        Ann. Surg. Oncol. 2006 Dec; 13: 1702-1710
        • Harter P.
        • Sehouli J.
        • Reuss A.
        • et al.
        Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOPII. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
        Int. J. Gynecol. Cancer. 2011 Feb; 21: 289-295
        • Du Bois A.
        • Vergote I.
        • Ferron G.
        • et al.
        Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: the interim analysis of AGO DESKTOP III/ENGOT OV20. Abst 5501.
        in: Proc ASCO. 2017
        • Chi D.S.
        • McCaughty K.
        • Diaz J.P.
        • et al.
        Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent platinum-sensitive epithelial ovarian carcinoma.
        Cancer. 2006 May 1; 106: 1933-1939
        • Cowan R.
        • Eriksson A.G.Z.
        • Jaber S.M.
        • et al.
        A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.
        Gynecol. Oncol. 2017 May; 145: 230-235
        • Janco J.M.
        • Kumar A.
        • Weaver A.L.
        • et al.
        Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
        Gynecol. Oncol. 2016 Apr; 14: 140-147
        • Coleman R.L.
        • Spirtos N.
        • Enserro D.
        • et al.
        A phase III randomized controlled trial of secondary cytoredutiction followed by platinum-based combination chemotherapy, with or without bevacizumab in platinum-sensitive, recurrent ovairan cancer: a NRG Oncology/Gynecologic Oncology Group Study, Abstr 5501.
        in: Proc ASCO. 2018
        • Parmar M.K.B.
        • Torri V.
        • Stewart L.
        Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
        Stat. Med. 1998; 17: 2815-2834